Enfortumab vedotin Approved for Marketing Phase N/A Trials for Locally Advanced or Metastatic Urothelial Carcinoma (UC)

IndicationsStatusPurposePhase
Approved for MarketingNot AvailableNot Available
clinicaltrials.gov IdentifierTitleDrugs
NCT04136808An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma